Immunoblotting showed USP5 protein levels were also downregulated after 48 h of combination treatment in MYCN-amplified Kelly and SK-N-BE(2)-C cells, as well as in the MDA-MB-231 breast cancer line (Fig. 4b; Fig. S4b, c). The gene discussed is USP5; the disease is breast carcinoma.